Skip to content
Evigrade
CriticalErgot alkaloid, 5-HT1B/1D and alpha-adrenoceptor agonist×Triptan, selective 5HT1B/1D receptor agonist

Updated · Methodology

Mechanism

Both drugs constrict blood vessels. Zolmitriptan is a selective agonist of the 5-HT1B and 5-HT1D serotonin receptors that mediate vascular contraction, and in animal models it constricts the carotid arteries (zolmitriptan summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). Dihydroergotamine, an ergotamine derivative, binds to 5-HT1D receptors, and its main metabolite is as potent a venoconstrictor as the parent drug. Like other ergot alkaloids, dihydroergotamine can cause spasm of the coronary and other arteries (dihydroergotamine labels, US Food and Drug Administration, FDA). The US zolmitriptan label states that ergot drugs cause prolonged vasospasm that may add to the effect of zolmitriptan (zolmitriptan label, FDA, section 7.1). The Spanish SmPC calls the higher risk of coronary vasospasm with ergotamine a theoretical possibility (AEMPS, section 4.5). In interaction studies dihydroergotamine caused no clinically important change in the pharmacokinetics of zolmitriptan or its active metabolite (zolmitriptan SmPC, AEMPS, section 4.5).

Symptoms

Reactions to zolmitriptan usually appear within four hours. Common reactions are heaviness, tightness, pain or pressure in the throat, neck, limbs and chest, and palpitations. Transient rises in blood pressure are less common. Coronary vasospasm, angina, myocardial infarction and ischaemia or infarction of the bowel and spleen with bloody diarrhoea or abdominal pain are very rare (zolmitriptan summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.4 and 4.8). Life-threatening ventricular tachycardia and ventricular fibrillation have been reported within a few hours of 5-HT1 agonists (zolmitriptan label, US Food and Drug Administration, FDA, section 5.2), and myocardial infarction, life-threatening arrhythmias and transient myocardial ischaemia after dihydroergotamine (dihydroergotamine labels, FDA). Vasospasm from dihydroergotamine causes muscle pain, numbness, coldness, pallor and bluish discolouration of the fingers and toes, and ischaemia of the limbs and colon. In people with poor circulation, persistent vasospasm can lead to gangrene or death. On rare occasions, blood pressure rises sharply (dihydroergotamine labels, FDA).

Management

The combination is contraindicated. The Spanish zolmitriptan summary of product characteristics (SmPC) contraindicates zolmitriptan with ergotamine and ergotamine derivatives (zolmitriptan SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 4.3). Dihydroergotamine is an ergotamine derivative and is not in the Spanish medicines register. The US zolmitriptan label names dihydroergotamine and contraindicates taking the two drugs within 24 hours of each other (zolmitriptan label, US Food and Drug Administration, FDA, sections 4 and 7.1). The dihydroergotamine labels contraindicate dihydroergotamine in patients who have taken triptans in the previous 24 hours (dihydroergotamine labels, FDA). Keep at least 24 hours between the two drugs, in either order (zolmitriptan and dihydroergotamine labels, FDA). The Spanish zolmitriptan SmPC gives intervals only for ergotamine-containing products (24 hours before zolmitriptan and 6 hours after it) and none for dihydroergotamine (AEMPS, section 4.5). If chest pain or other signs of cardiac ischaemia appear, withhold further zolmitriptan doses until a doctor has assessed the patient (zolmitriptan SmPC, AEMPS, section 4.4). Stop zolmitriptan if arrhythmias occur (zolmitriptan label, FDA, section 5.2). Stop dihydroergotamine at once if signs of vasoconstriction appear (dihydroergotamine labels, FDA), and rule out vasospasm before the next zolmitriptan dose (zolmitriptan label, FDA, section 5.5). Monitor blood pressure during zolmitriptan treatment (zolmitriptan label, FDA, section 5.8). Zolmitriptan is contraindicated in moderate or severe hypertension and in uncontrolled mild hypertension (AEMPS, section 4.3), and dihydroergotamine in uncontrolled hypertension (dihydroergotamine labels, FDA). Taking acute migraine drugs, including triptans and ergot drugs, on 10 or more days a month can make headaches more frequent (zolmitriptan and dihydroergotamine labels, FDA). If medication overuse headache is suspected, interrupt treatment (zolmitriptan SmPC, AEMPS, section 4.4).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Dihydroergotamine

Other interactions with Zolmitriptan